AP Biosciences

AP Biosciences FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of AP Biosciences (6945.TWO) as of Nov 17, 2026 is 84.84 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 85.96 % — a change of -1.30% (lower).

FCF Conversion

84.84 %

YoY

-1.30%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of AP Biosciences is 2025 84.84 % . FCF Conversion Rate (FCF/EBITDA) of AP Biosciences was 2024 85.96 % . It decreases by -1.30% lower compared to the previous year.

The AP Biosciences FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2020
-58.20 TWD
Jan 1, 2021
92.53 TWD
Jan 1, 2022
96.49 TWD
Jan 1, 2023
98.15 TWD
Jan 1, 2024
85.96 TWD
Jan 1, 2025
84.84 TWD
The AP Biosciences FCF Conversion history
YEARFCF ConversionYoY
84.84 %-1.30%
85.96 %-12.42%
98.15 %+1.72%
96.49 %+4.28%
92.53 %-258.99%
-58.20 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AP Biosciences Stock analysis

What does AP Biosciences do? AP Biosciences Inc generates revenue through the development and commercialization of protein and antibody drugs. The company focuses on early-stage drug candidates and preclinical trials, utilizing its technology platforms to create monoclonal and bispecific antibody drugs. Key products include IBI302, OmniMab, AP505, T-cube, and AP203, which target specific disease mechanisms and therapeutic areas. The primary buyers are pharmaceutical companies seeking to expand their drug pipelines through partnerships and licensing agreements. The firm's technology platforms, such as OmniMab fully human antibody library and T-cube, enable the development of novel bispecific antibodies. These platforms support the creation of drugs like AP505-PD-L1 x VEGF bispecific antibody and AP203-PD-L1 x CD137 fully human bispecific antibody, which are designed for specific therapeutic targets. The company's research and development efforts target diseases with high unmet medical needs, attracting interest from potential collaborators in the biopharmaceutical sector. AP Biosciences Inc's business model relies on advancing its pipeline of drug candidates through preclinical and clinical stages, with the goal of securing partnerships or licensing deals with larger pharmaceutical firms. The company's focus on bispecific antibody technology and its proprietary platforms positions it to generate revenue from milestone payments and royalties upon successful development and commercialization of its drug candidates. AP Biosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AP Biosciences stock

FCF Conversion Rate (FCF/EBITDA) of AP Biosciences is 84.84 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of AP Biosciences changed from 85.96 % to 84.84 %, representing a -1.30% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) AP Biosciences since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s AP Biosciences with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — AP Biosciences

All Key Metrics — AP Biosciences